Applying the taguchi design for optimized formulation of sustained release gliclazide chitosan beads: An in vitro/in vivo study

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 158-165

  Varshosaz, J ^a   Tavakoli, N ^a   Minayian, M ^a   Rahdari, N ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood glucose; Chitosan beads; Controlled drug delivery; Gliclazide; Streptozotocin diabetic rats

Indexed keywords

CHITOSAN; GLICLAZIDE; GLUCOSE; ISOPHANE INSULIN; TRIPOLYPHOSPHATE; ANTIDIABETIC AGENT; CROSS LINKING REAGENT; DRUG CARRIER; POLYPHOSPHATE; TRIPHOSPHORIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION PROCESS; CONTROLLED STUDY; CROSS LINKING; DIABETES MELLITUS; DISPERSION; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PH; PROCESS OPTIMIZATION; RAT; STREPTOZOCIN DIABETES; SUSTAINED DRUG RELEASE; ANIMAL; BLOOD; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GEL; KINETICS; METHODOLOGY; PHARMACEUTICS; SOLUBILITY; STATISTICAL MODEL; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CROSS-LINKING REAGENTS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DRUG CARRIERS; DRUG COMPOUNDING; GELS; GLICLAZIDE; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; KINETICS; MALE; MODELS, STATISTICAL; MOLECULAR WEIGHT; PARTICLE SIZE; POLYPHOSPHATES; RATS; RATS, WISTAR; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 67549145650     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9191-8     Document Type: Article

References (54)

1. J. A. K. Lauwo, D. K. Agrawal, and I. V. Emenike. Some pharmaceutical studies on sustained release coprecipitates of ampicillin-trihydrate with acrylic resin (Eudragit®-RS). Drug Dev. Ind. Pharm. 16:1375-1389 (1990).
2. R. Bodmeier, H. Chen, P. Tyle, and P. Jarosz. Pseudophedrine HCL microspheres formulated into an oral suspension dosage form. J. Control. Release. 15:65-77 (1991).
3. A. K. Anal, W. F. Stevens, and C. Remuñn-López. Ionotropic cross-linked chitosan microspheres for controlled release of ampicillin. Int. J. Pharm. 312(1-2):166-173 (2006).
4. I. M. van der Lubben, J. C. Verhoef, G. Borchard, and H. E. Junginger. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52:139-144 (2001).
5. A. D. Martino, M. Sittinger, and M. V. Risbud. Chitosan: A versatile biopolymer for orthopaedic tissue-engineering. Biomaterials. 26:5983-5990 (2005).
6. L. Y. Wang, Y. H. Gu, Q. Z. Zhou, G. H. Ma, Y. H. Wan, and Z. G. Su. Preparation and characterization of uniform-sized chitosan microspheres containing insulin by membrane emulsification and a two-step solidification process. Colloids Surf., B: Biointerfaces. 50:126-135 (2006).
7. J. Wu, W. Wei, L. Y. Wang, Z. G. Su, and G. H. Ma. Preparation of uniform-sized pH-sensitive quaternized chitosan microsphere by combining membrane emulsification technique and thermal-gelation method. Colloids Surf., B: Biointerfaces. 63(2):164-175 (2008).
8. R. Bodmeier, K. H. Oh, and Y. Pramar. Preparation and evaluation of drug-containing chitosan beads. Drug Dev. Ind. Pharm. 15:1475-1494 (1989).
9. A. D. Sezer, and J. Akbûga. Release characteristics of chitosan treated alginate beads. I. Sustained release of a macromolecular drug from chitosan treated alginate beads. J. Microencap. 16(2):195-203 (1999).
10. A. K. Anal, D. Bhopatkar, S. Tokura, H. Tamura, and W. F. Stevens. Chitosan-alginate multilayer beads for gastric passage and controlled intestinal release of protein. Drug Dev. Ind. Pharm. 29:713-724 (2003).
11. A. K. Anal, and W. F. Stevens. Chitosan-alginate multilayer beads for controlled release of ampicillin. Int. J. Pharm. 290:45-54 (2005).
12. D. Bhopatkar, A. K. Anal, and W. F. Stevens. Ionotropic alginate beads for controlled intestinal protein delivery: Effect of chitosan and barium counterions on entrapment and release. J. Microencap. 22:91-100 (2005).
13. C. Remuñán-López, and R. Bodmeier. Effect of formulation and process variables on the formation of chitosan-gelatin coacervates. Int. J. Pharm. 135:63-72 (1996).
14. R. O. Williams III, M. K. Barron, M. J. Alonso, and C. Remuñán-López. Investigation of a pMDI formulation containing chitosan microspheres. Int. J. Pharm. 174:209-222 (1998).
15. P. He, S. S. Davis, and L. Illum. Chitosan microspheres prepared by spray drying. Int. J. Pharm. 187:53-65 (1999).
16. C. Remuñán-López, M. L. Lorenzo-Lamosa, J. L. Vila-Jato, and M. J. Alonso. Development of new chitosan-cellulose multicore microparticles for controlled drug delivery. Eur. J. Pharma. Biopharm. 45:49-56 (1998).
17. F. L. Mi, S. S. Shyu, T. Wong, S. F. Jang, S. T. Lee, and K. T. Lu. Chitosan-polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. II. Effect of pH-dependent ionic cross-linking or interpolymer complex using tripolyphosphate or polyphosphate reagent. J. Appl. Polym. Sci. 74:1093-1107 (1999).
18. J. A. Ko, H. J. Park, S. J. Hwang, J. B. Park, and J. S. Lee. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int. J. Pharm. 249(1-2):165-174 (2002).
19. F. L. Mi, S. S. Shyu, C. T. Chen, and J. Y. Schoung. Porous chitosan microsphere for controlling the antigen release of Newcastle disease vaccine: Preparation of antigen-adsorbed microsphere and in vitro release. Biomaterials. 20(17):1603-1612 (1999).
20. S. Nakai, K. Koide, and K. Eugster. A new mapping super-simplex optimization for food product and process development. J. Food Sci. 49:1143-1170 (1984).
21. K. C. Chen, T. C. Lee, and J. Y. Houng. Search method for the optimal medium for the production of lactase by Kluyveromyces fragilis. Enzyme Microb. Technol. 14:659-664 (1992).
22. R. Banerjii, and B. C. Bhattacharyya. Evolutionary operation (EVOP) to optimize three-dimensional biological experiments. Biotechnol. Bioeng. 41:67-71 (1993).
23. R. Tunga, R. Banerjii, and B. C. Bhattacharyya. Optimization of n variable biological experiments by evolutionary operation-fractional design technique. J. Biosci. Bioeng. 87(2):224-230 (1999).
24. J. Y. Houng, K. C. Chen, and W. H. Hsu. Optimization of cultivation medium composition for isoamylase production. Appl. Microb. Biotechnol. 31:61-64 (1989).
25. S. Chopra, G. V. Patil, and S. K. Motwani. Release modulating hydrophilic matrix systems of losartan potassium: Optimization of formulation using statistical experimental design. Eur. J. Pharm. Biopharm. 66:73-82 (2007).
26. O. Sreekumar, N. Chand, and A. C. Basappa. Optimization and interaction of media components in ethanol production using Zymomonas mobilis by response surface methodology. J. Biosci. Bioeng. 88(3):334-338 (1999).
27. M. Jahanshahi, G. Najafpour, and M. Rahimnejad. Applying the Taguchi method for optimized fabrication of bovine serum albumin (BSA) nanoparticles as drug delivery vehicles. Afr. J. Biotechnol. 7(4):362-367 (2008).
28. B. D. Cobb, and J. M. Clarkson. A simple procedure for optimising the polymerase chain reaction (PCR) using modified Taguchi methods. Nucleic Acids Res. 22(18):3801-3805 (1994).
29. R. A. Stone, and A. Veevers. The Taguchi influence on designed experiments. J. Chemometr. 8:103-110 (1994).
30. J. D. Bendell, J. Disney, and W. A. Pridmore. Taguchi Methods: Applications in World Industry, IFS Publications, Bedford, 1989.
31. J. Y. Houng, H. F. Hsu, Y. H. Liu, and J. Y. Wu. Applying the Taguchi robust design to the optimization of the asymmetric reduction of ethyl 4-chloro acetoacetate by bakers' yeast. J. Biotechnol. 100(3):239-250 (2003).
32. F. K. Główka, T. W. Hermann, and M. Zabel. Bioavailability of gliclazide from some formulation tablets. Int. J. Pharm. 172(1-2):71-77 (1998).
33. D. B. Cambell, R. Lavielle, and C. Nathan. The mode of action and clinical pharmacology of gliclazide: A review. Diabetes Res. 14(Suppl):S21-S36 (1991).
34. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet. Med. 16:716-730 (1999).
35. A. Harrower. Gliclazide modified release: From once daily administration to 24-hour blood glucose control. Metabolism. 49(suppl 2):7-11 (2000).
36. M. Francillard, N. Frey, and M. Paraire. Pharmacokinetics of diamicron modified release (MR) in 1007 type 2 diabetic patients. J. Nutr. Health Aging. 5:31 (2001).
37. P. Delrat, M. Paraire, and R. Jochemsen. Complete bioavailability and lack of food effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm. Drug Dispos. 23:151-157 (2002).
38. F. M. Gribble, and F. M. Ashcroft. Differential sensitivity of β-cell and extrapancreatic K ATP channels to gliclazide. Diabetologia. 42:845-848 (1999).
39. F. M. Gribble, S. J. Tucker, and S. Seino. Tissue specificity of sulfonylureas: Studies on cloned cardiac and β cell KATP channels. Diabetes. 47:1412-1418 (1998).
40. G. Schernthaner. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism. 52(Suppl 1):29-34 (2003).
41. G. Taguchi. System of Experimental Design. Engineering Methods to Optimize Quality and Minimize Costs, Kraus International, White Plains, New York, 1987.
42. W. Y. Fowlkes, and C. M. Creveling. Engineering Methods for Robust Product Design. Using Taguchi Methods® in Technology and Product Development, Addison-Wesley, New York, 1995.
43. W. C. Lin, D. G. Yu, and M. C. Yang. pH-sensitive polyelectrolyte complex gel microspheres composed of chitosan/sodium tripolyphosphate/ dextran sulfate: Swelling kinetics and drug delivery properties. Colloids Surf., B: Biointerfaces. 44(2-3):143-151 (2005).
44. J. A. Ko, H. J. Park, S. J. Hwang, J. B. Park, and J. S. Lee. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int. J. Pharm. 249(1-2):165-174 (2002).
45. P. Costa, J. Manuel, and S. Lobo. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 13:123-133 (2001).
46. 2 factorial design. Drug Dev. Ind. Pharm. 28(1):77-87 (2002).
47. A. Eidi, M. Eidi, and M. Sokhteh. Effect of fenugreek (Trigonella foenum-graecum L) seeds on serum parameters in normal and streptozotocin-induced diabetic rats. Nutr. Res. 27(11):728-733 (2007).
48. G. Suresh Kumar, A. K. Shetty, K. Sambaiah, and P. V. Salimath. Antidiabetic property of fenugreek seed mucilage and spent turmeric in streptozotocin-induced diabetic rats. Nutr. Res. 25(11):1021-1028 (2005).
49. A. Chandra, A. A. Mahdi, S. Ahmad, and R. K. Singh. Indian herbs result in hypoglycemic responses in streptozotocin-induced diabetic rats. Nutr. Res. 27(3):161-168 (2007).
50. N. Pulido, A. Suarez, B. Casanova, R. Romero, E. Rodriguez, and A. Rovira. Gliclazide treatment of streptozotocin diabetic rats restores GLUT4 protein content and basal glucose uptake in skeletal muscle. Metabolism. 46(Suppl 1):10-13 (1997).
51. X. Qiang, J. Satoh, M. Sagara, M. Fukuzawa, T. Masuda, S. Miyaguchi, K. Takahashi, and T. Toyota. Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats. Metabolism. 47(8):977-981 (1998).
52. K. J. Palmer, and R. N. Brogden. Gliclazide, an update of its pharmacological properties and therapeutic efficacy non-insulin-dependent diabetes mellitus. Drugs. 46:92-125 (1993).
53. J. Duhault, M. Boulanger, and F. Tisserand. The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties. Arzneim Forsch. 22:1682-1685 (1972).
54. A. E. Pontiroli, A. Calderara, and G. Pozza. Secondary failure of oral hypoglycaemic agents: Frequency, possible causes, and management. Diabetes Metab. Rev. 10:31-43 (1994).